199 related articles for article (PubMed ID: 34513277)
1. Liver: glucose metabolism and 18F-fluorodeoxyglucose PET findings in normal parenchyma and diseases.
Sarikaya I; Schierz JH; Sarikaya A
Am J Nucl Med Mol Imaging; 2021; 11(4):233-249. PubMed ID: 34513277
[TBL] [Abstract][Full Text] [Related]
2. Radiation-Induced Metabolic Shifts in the Hepatic Parenchyma: Findings from
Chung YH; Tsai CK; Yu CF; Wang WL; Yang CL; Hong JH; Yen TC; Chen FH; Lin G
Molecules; 2021 Apr; 26(9):. PubMed ID: 33925109
[TBL] [Abstract][Full Text] [Related]
3. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
4. Imaging of cardiac metabolism using radiolabelled glucose, fatty acids and acetate.
Visser FC
Coron Artery Dis; 2001 Feb; 12 Suppl 1():S12-8. PubMed ID: 11286301
[TBL] [Abstract][Full Text] [Related]
5. 18F-fluorodeoxyglucose (FDG)-PET features of focal nodular hyperplasia (FNH) of the liver.
Kurtaran A; Becherer A; Pfeffel F; Müller C; Traub T; Schmaljohann J; Kaserer K; Raderer M; Schima W; Dudczak R; Kletter K; Virgolini I
Liver; 2000 Dec; 20(6):487-90. PubMed ID: 11169064
[TBL] [Abstract][Full Text] [Related]
6. Fluorine-18 FDG positron emission tomography for imaging of hepatocellular carcinoma.
Trojan J; Schroeder O; Raedle J; Baum RP; Herrmann G; Jacobi V; Zeuzem S
Am J Gastroenterol; 1999 Nov; 94(11):3314-9. PubMed ID: 10566736
[TBL] [Abstract][Full Text] [Related]
7. Uncoupling of fatty acid and glucose metabolism in malignant lymphoma: a PET study.
Nuutinen J; Minn H; Bergman J; Haaparanta M; Ruotasalainen U; Laine H; Knuuti J
Br J Cancer; 1999 May; 80(3-4):513-8. PubMed ID: 10408861
[TBL] [Abstract][Full Text] [Related]
8. Hypoxia and glucose metabolism in malignant tumors: evaluation by [18F]fluoromisonidazole and [18F]fluorodeoxyglucose positron emission tomography imaging.
Rajendran JG; Mankoff DA; O'Sullivan F; Peterson LM; Schwartz DL; Conrad EU; Spence AM; Muzi M; Farwell DG; Krohn KA
Clin Cancer Res; 2004 Apr; 10(7):2245-52. PubMed ID: 15073099
[TBL] [Abstract][Full Text] [Related]
9. An evaluation of myocardial fatty acid and glucose uptake using PET with [18F]fluoro-6-thia-heptadecanoic acid and [18F]FDG in Patients with Congestive Heart Failure.
Taylor M; Wallhaus TR; Degrado TR; Russell DC; Stanko P; Nickles RJ; Stone CK
J Nucl Med; 2001 Jan; 42(1):55-62. PubMed ID: 11197981
[TBL] [Abstract][Full Text] [Related]
10. Characteristics of myocardial 18F-fluorodeoxyglucose positron emission computed tomography in dilated cardiomyopathy and ischemic cardiomyopathy.
Yamaguchi H; Hasegawa S; Yoshioka J; Uehara T; Hashimoto K; Kusuoka H; Kuzuya T; Hori M; Nishimura T
Ann Nucl Med; 2000 Feb; 14(1):33-8. PubMed ID: 10770578
[TBL] [Abstract][Full Text] [Related]
11. Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumours.
Adams S; Baum R; Rink T; Schumm-Dräger PM; Usadel KH; Hör G
Eur J Nucl Med; 1998 Jan; 25(1):79-83. PubMed ID: 9396878
[TBL] [Abstract][Full Text] [Related]
12. Clinical applications and advances of positron emission tomography with fluorine-18-fluorodeoxyglucose (18F-FDG) in the diagnosis of liver neoplasms.
He YX; Guo QY
Postgrad Med J; 2008 May; 84(991):246-51. PubMed ID: 18508981
[TBL] [Abstract][Full Text] [Related]
13. Hepatic steatosis is associated with abnormal hepatic enzymes, visceral adiposity, altered myocardial glucose uptake measured by
Hu L; Shao X; Qiu C; Shao X; Wang X; Niu R; Wang Y
BMC Endocr Disord; 2020 May; 20(1):75. PubMed ID: 32460891
[TBL] [Abstract][Full Text] [Related]
14. Standardized uptake values of normal organs on 18F-fluorodeoxyglucose positron emission tomography and computed tomography imaging.
Zincirkeser S; Sahin E; Halac M; Sager S
J Int Med Res; 2007; 35(2):231-6. PubMed ID: 17542410
[TBL] [Abstract][Full Text] [Related]
15. Analysis of adrenal masses by 18F-FDG positron emission tomography scanning.
Han SJ; Kim TS; Jeon SW; Jeong SJ; Yun M; Rhee Y; Kang ES; Cha BS; Lee EJ; Lee HC; Lim SK
Int J Clin Pract; 2007 May; 61(5):802-9. PubMed ID: 17343665
[TBL] [Abstract][Full Text] [Related]
16. Respiratory gated and prolonged acquisition 18F-FDG PET improve preoperative assessment of colorectal liver metastases.
Revheim ME; Haugvik SP; Johnsrud K; Mathisen Ø; Fjeld JG; Skretting A
Acta Radiol; 2015 Apr; 56(4):397-403. PubMed ID: 24682406
[TBL] [Abstract][Full Text] [Related]
17. Revisit 18F-fluorodeoxyglucose oncology positron emission tomography: "systems molecular imaging" of glucose metabolism.
Shen B; Huang T; Sun Y; Jin Z; Li XF
Oncotarget; 2017 Jun; 8(26):43536-43542. PubMed ID: 28402949
[TBL] [Abstract][Full Text] [Related]
18. The difference between steroid diabetes mellitus and type 2 diabetes mellitus: a whole-body
Zhao Q; Zhou J; Pan Y; Ju H; Zhu L; Liu Y; Zhang Y
Acta Diabetol; 2020 Nov; 57(11):1383-1393. PubMed ID: 32647998
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of benign vs malignant hepatic lesions with positron emission tomography.
Delbeke D; Martin WH; Sandler MP; Chapman WC; Wright JK; Pinson CW
Arch Surg; 1998 May; 133(5):510-5; discussion 515-6. PubMed ID: 9605913
[TBL] [Abstract][Full Text] [Related]
20. The use of 18F-Fluoro-deoxy-glucose positron emission tomography (18F-FDG PET) as a non-invasive pharmacodynamic biomarker to determine the minimally pharmacologically active dose of AZD8835, a novel PI3Kα inhibitor.
Maynard J; Emmas SA; Ble FX; Barjat H; Lawrie E; Hancox U; Polanska UM; Pritchard A; Hudson K
PLoS One; 2017; 12(8):e0183048. PubMed ID: 28806782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
